Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

ClinicalTrials.gov ID: NCT05832931

Public ClinicalTrials.gov record NCT05832931. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage Kidney Disease on Hemodialysis (PATH-1) With an Open-Label Extension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.

Study identification

NCT ID
NCT05832931
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pathalys Pharma
Industry
Enrollment
362 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 27, 2023
Primary completion
Jul 27, 2025
Completion
Jul 27, 2025
Last update posted
Sep 8, 2025

2023 – 2025

United States locations

U.S. sites
49
U.S. states
21
U.S. cities
44
Facility City State ZIP Site status
Site Number: USA016-1 Pine Bluff Arkansas 71603-4921
Site Number: USA032-1 Anaheim California 92801-2817
Site Number: USA031-1 Beverly Hills California 90211-2921
Site Number: USA020-1 Fairfield California 94534
Site Number: USA023-1 Fullerton California 92835-3639
Site Number: USA030-1 Glendale California 91206-4015
Site Number: USA045-1 Oxnard California 93036-3075
Site Number: USA046-1 Riverside California 92505-3081
Site Number: USA035-1 Salinas California 93901-4446
Site Number: USA001-1 San Diego California 92111-3636
Site Number: USA021-1 San Diego California 92111-3636
Site Number: USA019-1 San Dimas California 91773-3537
Site Number: USA036-1 Whittier California 90606-3007
Site Number: USA018-1 Denver Colorado 80210-5073
Site Number: USA003-1 Lone Tree Colorado 80124-3191
Site Number: USA009-1 Hartford Connecticut 06112-1272
Site Number: USA042-1 Coral Gables Florida 33134-2049
Site Number: USA055-1 Coral Gables Florida 33134-2060
Site Number: USA034-1 Hollywood Florida 33024-2776
Site Number: USA053-1 Atlanta Georgia 30342-1626
Site Number: USA013-1 Dalton Georgia 30720
Site Number: USA027-1 Boise Idaho 83706-1248
Site Number: USA007-1 Shelbyville Indiana 46176-8591
Site Number: USA026-1 Baton Rouge Louisiana 70808-4791
Site Number: USA015-1 Columbus Mississippi 39705-2024
Site Number: USA028-1 Oxford Mississippi 38655
Site Number: USA022-1 Kansas City Missouri 64111-2925
Site Number: USA017-1 Las Vegas Nevada 89107-6100
Site Number: USA010-1 Jersey City New Jersey 07305
Site Number: USA008-1 Gallup New Mexico 87301-5611
Site Number: USA039-1 Manhasset New York 11030-3802
Site Number: USA011-1 The Bronx New York 10461-2755
Site Number: USA052-1 Charlotte North Carolina 28277-9720
Site Number: USA043-1 Greenville North Carolina 27834-4300
Site Number: USA033-1 Winston-Salem North Carolina 27103-7154
Site Number: USA040-1 Spartanburg South Carolina 29301-5085
Site Number: USA049-1 Knoxville Tennessee 37924-3606
Site Number: USA037-1 Arlington Texas 76015-2363
Site Number: USA024-1 Austin Texas 78751-3014
Site Number: USA056-1 Fort Worth Texas 76110-1865
Site Number: USA014-1 Houston Texas 77054-3835
Site Number: USA012-1 Houston Texas 77074-1802
Site Number: USA025-1 McAllen Texas 78503-1251
Site Number: USA029-1 San Antonio Texas 78202-2916
Site Number: USA005-1 San Antonio Texas 78229-4605
Site Number: USA004-1 San Antonio Texas 78251-4498
Site Number: USA002-1 The Woodlands Texas 77384-8042
Site Number: USA006-1 Norfolk Virginia 23504-2303
Site Number: USA050-1 Wauwatosa Wisconsin 53226-4339

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05832931, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 8, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05832931 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →